News Column

Ignyta Appoints Adrian Senderowicz, M.D., as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs

August 25, 2014



By a News Reporter-Staff News Editor at Clinical Trials Week -- Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced that Adrian Senderowicz, M.D., has been appointed as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs (see also Ignyta, Inc.).

"Adrian's deep experience in clinical, research, development and regulatory affairs in the oncology setting will be extremely valuable to Ignyta," said Jonathan Lim, M.D., Chairman and CEO of Ignyta. "His extensive experience in large pharma and biotech, as well as with the FDA and NCI, will make him instrumental to the company's success as we strive to provide new treatment options for patients with our proprietary oncology drug development programs."

Dr. Senderowicz was most recently Vice President, Global Regulatory Oncology at Sanofi, a position he held from September 2013 to August 2014. At Sanofi, Dr. Senderowicz oversaw the global Sanofi oncology portfolio, including 17 new molecular entities and approximately 250 ongoing oncology and transplant protocols. From July 2012 to March 2013, Dr. Senderowicz was Chief Medical Officer at Tokai Pharmaceuticals, where he wrote the protocol and led the initiation of the ARMOR Phase II clinical trial for the evaluation of galeterone in prostate cancer and played a key role in Tokai's$36 million Series E financing. Dr. Senderowicz held positions of increasing responsibility from July 2008 to March 2012 at Astra Zeneca, including Senior Medical Director, Oncology Clinical Development. At Astra Zeneca, he designed and conducted several global clinical trials in solid tumors, including serving as a Clinical Project Leader of vandetanib, which was approved in the U.S. in April 2011 and the European Union in March 2012, and executing a first-in-human Phase I trial of the Trk inhibitor AZD 6918 as part of the Oncology Phase I Team.

Keywords for this news article include: Oncology, Ignyta Inc..

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters